Cetuximab + Irinotecan + IMC-A12 (cixutumumab)
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colon Cancer
Conditions
Colon Cancer, Rectal Cancer
Trial Timeline
May 1, 2009 → Feb 1, 2011
NCT ID
NCT00845039About Cetuximab + Irinotecan + IMC-A12 (cixutumumab)
Cetuximab + Irinotecan + IMC-A12 (cixutumumab) is a phase 2 stage product being developed by Eli Lilly for Colon Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00845039. Target conditions include Colon Cancer, Rectal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00845039 | Phase 2 | Terminated |
Competing Products
20 competing products in Colon Cancer